FM-CATH, A Novel Cathelicidin From Fejervarya Multistriata, Shows Therapeutic Potential for Treatment of CLP-Induced Sepsis

• Published in: Frontiers in pharmacology 2021-08, Vol.12, p.731056-731056
• Main Authors: Wu, Jiena, Zhang, Haiyun, Chen, Xiaoxin, Chai, Jinwei, Hu, Yunrui, Xiong, Weichen, Lu, Wancheng, Tian, Maolin, Chen, Xin, Xu, Xueqing
• Format: Article
• Language: English
• Subjects: antimicrobial peptide; cathelicidin; cecal ligation and puncture; coagulation; lipopolysaccharide and lipoteichoic acid-neutralizing; Pharmacology; sepsis
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.731056

Sepsis is an exacerbated inflammatory reaction induced by severe infection. As important defensive molecules in innate immunity, several AMPs are reported to prevent septic shock. In this study, we characterized a novel cathelicidin, FM-CATH, from the frog skin of F. multistriata. FM-CATH was found to adopt an amphipathic α-helix structural in membrane-mimetic environments and possess favorable antimicrobial effects against bacteria and fungus. In addition, it triggered the agglutination of bacteria. It could also strongly bind to LPS and LTA. Additionally, FM-CATH affected the enzymatic activities of thrombin, plasmin, β-tryptase, and tPA, leading to coagulation inhibition in vitro and in vivo . Finally, we observed that FM-CATH improved survival rate and inhibited pathological alteration, bacterial count, serum biochemistry, and pro-inflammatory cytokine expression in the cecal ligation and puncture-induced sepsis mice. Taken together, these findings suggest that FM-CATH might be served as a promising agent for the treatment of sepsis.